Laboratory Corporation of America

  • Why This Health Care Play Looks Like a Good Value

    By Lee Samaha - June 14, 2013 | Tickers: AET, CI, HOLX, LH, DGX

    I'm more of a GARP orientated investor but I occasionally I dabble in some value stocks. I confess I get tempted by the sordid infidelity of it all. 

    A few years ago a well known UK fund manager outlined one approach to the art of value investing to me. In short it involved analyzing companies across a sector and finding one that was under-performing based on various key metrics more »

  • 3 Reasons Why Small Caps Rule

    By Phillip Woolgar - June 3, 2013 | Tickers: AGT, GLDD, LH

    When deciding on how much of your portfolio to dedicate to small-cap stocks, it's important to note many of the perks that come along with buying smaller companies. 

    The most obvious advantage to small caps is their tendency to outperform their large-cap counterparts. In fact, according to a report from investment consulting firm Ibbotson Associates, small caps increased in value by approximately 12% between 1927 and 2007. During the more »

  • Is This Ticking Time Bomb A Cornerstone of Your Portfolio?

    By Brendan O'Boyle - April 18, 2013 | Tickers: LH, LPNT, MYGN

    The Supreme Court is scheduled to hear a greatly anticipated case that will provide clarity on the patentability of human genes. Over the past thirty years, biotechnology innovators have secured patents on genes for purposes that range from medical to agricultural products. This Monday, a challenge to Myriad Genetics (NASDAQ: MYGN) was heard contesting whether or not their patent is valid. The Association for Molecular Pathology is challenging the patentability more »

  • Why This Stock Is an Interesting Value Play

    By Lee Samaha - January 25, 2013 | Tickers: LH, DGX

    Diagnostic testing company Quest Diagnostics (NYSE: DGX) caught my eye recently. It’s always nice to balance a portfolio by deliberately buying stocks whose prospects are not cyclically aligned, and Quest seems to fit the bill. In summary, the stock price driver is likely to be a combination of its internal reorganization plans plus the top line effect of reimbursement issues. It does have some cyclical upside from an improving more »

  • Healthcare Valuations Are Out of Whack

    By Ted Cooper - January 22, 2013 | Tickers: ALR, LH

    There is so much uncertainty surrounding the health care reform law that many stocks in the sector are trading out of line with their intrinsic value. This creates a buying opportunity for discerning investors who are willing to buy and hold these undervalued companies for many years.

    Although there is a high level of uncertainty in managed care providers and health insurers, there is less uncertainty as to the future more »

  • Buy This Wide-Moat Company

    By Ted Cooper - January 8, 2013 | Tickers: ALR, LH, DGX

    Companies that provide diagnostic lab testing for hospitals and managed care providers have been hit hard by the economic downturn, as many patients are visiting the doctor less often than they used to. However, this trend will likely reverse itself as the United States economy recovers and Obamacare is fully implemented.

    In the United States, diagnostic lab testing is dominated by two companies: Quest Diagnostic (NYSE: DGX) and LabCorp (NYSE: LHmore »)

  • The Price is Right at Quest Diagnostics

    By Steve Van - September 12, 2012 | Tickers: BRLI, LH, DGX

    Quest Diagnostics Inc. (NYSE: DGX) and Laboratory Corporation of America (NYSE: LH) are two giants in the diagnostic testing business which is experiencing shifting domestic population demographics, changing laws and regulations, and changing customer preferences.  Another player in the industry is the much smaller Bio-Reference Laboratories Inc. (NASDAQ: BRLI) which operates primarily in metro New York.  Quest's position as the market leader should result in above market returns for more »

  • 6 Undervalued Stocks That Could Take Off in 2012

    By Robert Fisher - January 28, 2012 | Tickers: APH, BDX, LH, RL, RCI, SNN

    With the uneven recovery taking place on Wall Street, investors are being forced to spend extra time researching companies and the prospect of their success. While a number of well-known companies have gotten off to a great start in 2012, there are still plenty of businesses that have yet to be discovered. Among these, six undervalued stocks with strong potential are Becton, Dickinson and Company (NYSE: BDX), Rogers Communication Inc more »

  • Quest or Labcorp – How About a Smaller Option?

    By Chad Henage - January 26, 2012 | Tickers: BRLI, LH, DGX

    When most people are asked by their doctor where they would like to go to get their blood drawn or a test done the choices are usually Quest Diagnostics (NYSE: DGX) or Labcorp (NYSE: LH). These two titans of the testing and analysis industry have more locations and are generally well known. In beginning to write this I expected to compare these two and see which looked like the better buy. Then something happened, I realized they have a much smaller competitor that is crushing both of their results. Who is this small fry in the same business? - Bio-Reference Laboratories (NASDAQ: BRLI).

  • Price The Market Part 40

    By Glen Bradford - January 12, 2012 | Tickers: LH, MCK, MHS.DL, MDT, MRK

    Hi, my name is Glen Bradford and I am sitting in a Developer Workshop at the University of South Florida. What am I doing? I'm sitting in the front row pricing the market. Let's do this.

    266. Laboratory Corp. of America Holding (NYSE: LH) looks relatively cheap to undervalued to me. Target: $85-$100. For their rate of growth their P/E isn't high enough more »